Firm notes that the sum of $24.5MM in exchange for 1% of the future worldwide sales of arimoclomol places a net present value (NPV) of approximately $2.5B on arimoclomol. In light of this non-dilutive financing arrangement, which firm views provides a significant lift to the clinical development of arimoclomol, firm retains its Market Outperform rating on CytRx shares with a price target of $3.50 per share